Megan Rech
Concepts (443)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pharmacists | 20 | 2026 | 260 | 7.500 |
Why?
| | Blood Coagulation Factors | 11 | 2026 | 71 | 6.220 |
Why?
| | Emergency Medicine | 16 | 2026 | 280 | 5.180 |
Why?
| | Sepsis | 16 | 2025 | 669 | 4.840 |
Why?
| | Emergency Service, Hospital | 44 | 2026 | 2363 | 4.790 |
Why?
| | Anticoagulants | 12 | 2026 | 746 | 4.040 |
Why?
| | Shock, Septic | 10 | 2023 | 230 | 3.540 |
Why?
| | Pharmacy Service, Hospital | 9 | 2026 | 90 | 3.390 |
Why?
| | Factor Xa Inhibitors | 5 | 2026 | 195 | 2.990 |
Why?
| | Intracranial Hemorrhages | 6 | 2026 | 106 | 2.960 |
Why?
| | Time-to-Treatment | 8 | 2025 | 257 | 2.690 |
Why?
| | Hemostatics | 3 | 2025 | 66 | 2.260 |
Why?
| | Vasoconstrictor Agents | 6 | 2024 | 148 | 2.230 |
Why?
| | Cerebral Hemorrhage | 4 | 2025 | 125 | 2.090 |
Why?
| | Tranexamic Acid | 4 | 2022 | 63 | 2.060 |
Why?
| | Warfarin | 5 | 2021 | 179 | 2.050 |
Why?
| | Drug Therapy | 4 | 2026 | 85 | 2.020 |
Why?
| | Anesthetics, Local | 3 | 2026 | 106 | 1.990 |
Why?
| | Anti-Bacterial Agents | 12 | 2026 | 1942 | 1.920 |
Why?
| | Hemorrhage | 8 | 2026 | 825 | 1.860 |
Why?
| | Etomidate | 3 | 2023 | 23 | 1.850 |
Why?
| | Acute Pain | 3 | 2022 | 58 | 1.790 |
Why?
| | Factor Xa | 2 | 2025 | 36 | 1.780 |
Why?
| | Tissue Plasminogen Activator | 4 | 2022 | 245 | 1.780 |
Why?
| | Critical Illness | 11 | 2026 | 908 | 1.670 |
Why?
| | Fibrinolytic Agents | 7 | 2026 | 303 | 1.650 |
Why?
| | Tachycardia, Supraventricular | 3 | 2023 | 50 | 1.570 |
Why?
| | Humans | 127 | 2026 | 146342 | 1.550 |
Why?
| | Ketamine | 4 | 2023 | 144 | 1.540 |
Why?
| | Deamino Arginine Vasopressin | 2 | 2025 | 15 | 1.510 |
Why?
| | Critical Care | 8 | 2026 | 706 | 1.480 |
Why?
| | Retrospective Studies | 45 | 2026 | 17438 | 1.480 |
Why?
| | Eye | 2 | 2023 | 112 | 1.470 |
Why?
| | Professional Role | 9 | 2026 | 172 | 1.430 |
Why?
| | Intensive Care Units | 8 | 2022 | 925 | 1.330 |
Why?
| | Platelet Aggregation Inhibitors | 3 | 2025 | 499 | 1.250 |
Why?
| | Vitamin D Deficiency | 3 | 2019 | 189 | 1.200 |
Why?
| | Hospital Mortality | 7 | 2025 | 1051 | 1.180 |
Why?
| | Burns | 3 | 2019 | 365 | 1.170 |
Why?
| | Blood Coagulation Disorders | 2 | 2022 | 190 | 1.140 |
Why?
| | Vitamin D | 3 | 2019 | 402 | 1.090 |
Why?
| | Pyridones | 4 | 2026 | 210 | 1.070 |
Why?
| | Adrenal Insufficiency | 2 | 2020 | 31 | 1.070 |
Why?
| | Seizures | 4 | 2022 | 489 | 1.060 |
Why?
| | Pyrazoles | 5 | 2026 | 517 | 1.050 |
Why?
| | Pyelonephritis | 2 | 2024 | 13 | 1.040 |
Why?
| | Hypnotics and Sedatives | 7 | 2025 | 223 | 1.040 |
Why?
| | Stroke | 6 | 2026 | 1287 | 1.020 |
Why?
| | Hematoma | 2 | 2025 | 62 | 1.010 |
Why?
| | Aged | 34 | 2026 | 26432 | 0.990 |
Why?
| | Neuromuscular Blocking Agents | 2 | 2025 | 28 | 0.980 |
Why?
| | Succinylcholine | 2 | 2023 | 7 | 0.980 |
Why?
| | Middle Aged | 39 | 2026 | 36619 | 0.950 |
Why?
| | Infusions, Intravenous | 4 | 2025 | 432 | 0.950 |
Why?
| | Hyperkalemia | 1 | 2026 | 35 | 0.920 |
Why?
| | Potassium | 1 | 2026 | 151 | 0.920 |
Why?
| | Anti-Arrhythmia Agents | 2 | 2023 | 144 | 0.920 |
Why?
| | Anesthesia, Conduction | 1 | 2026 | 43 | 0.890 |
Why?
| | Face | 2 | 2023 | 177 | 0.890 |
Why?
| | Neuromuscular Nondepolarizing Agents | 2 | 2026 | 34 | 0.860 |
Why?
| | Personality | 1 | 2026 | 132 | 0.840 |
Why?
| | Nerve Block | 1 | 2026 | 114 | 0.840 |
Why?
| | Thrombosis | 3 | 2025 | 398 | 0.820 |
Why?
| | Amyloid | 1 | 2025 | 90 | 0.810 |
Why?
| | Female | 49 | 2026 | 79499 | 0.780 |
Why?
| | Deprescriptions | 1 | 2024 | 38 | 0.770 |
Why?
| | Male | 46 | 2026 | 73396 | 0.760 |
Why?
| | Norepinephrine | 2 | 2023 | 201 | 0.750 |
Why?
| | Organ Dysfunction Scores | 2 | 2020 | 55 | 0.750 |
Why?
| | Calcium Channel Blockers | 1 | 2023 | 165 | 0.740 |
Why?
| | Periodicals as Topic | 4 | 2021 | 214 | 0.740 |
Why?
| | Gastrointestinal Hemorrhage | 2 | 2022 | 134 | 0.740 |
Why?
| | United States | 19 | 2026 | 16136 | 0.730 |
Why?
| | Thrombelastography | 2 | 2020 | 182 | 0.720 |
Why?
| | Cycloserine | 1 | 2022 | 5 | 0.710 |
Why?
| | Heart Arrest | 3 | 2024 | 411 | 0.710 |
Why?
| | Sexually Transmitted Diseases | 1 | 2024 | 163 | 0.690 |
Why?
| | Thiamine | 1 | 2021 | 19 | 0.690 |
Why?
| | Biomedical Research | 2 | 2026 | 729 | 0.670 |
Why?
| | Triage | 3 | 2021 | 243 | 0.660 |
Why?
| | Cerebral Intraventricular Hemorrhage | 1 | 2020 | 6 | 0.640 |
Why?
| | Analgesics, Non-Narcotic | 1 | 2022 | 129 | 0.640 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 3 | 2026 | 344 | 0.640 |
Why?
| | Spinal Cord Injuries | 1 | 2024 | 238 | 0.630 |
Why?
| | Tetracaine | 1 | 2020 | 6 | 0.630 |
Why?
| | Intracranial Hemorrhage, Traumatic | 1 | 2020 | 11 | 0.630 |
Why?
| | Antihypertensive Agents | 2 | 2021 | 519 | 0.630 |
Why?
| | Ascorbic Acid | 1 | 2021 | 183 | 0.620 |
Why?
| | Oseltamivir | 1 | 2020 | 17 | 0.610 |
Why?
| | Heat Stroke | 1 | 2019 | 5 | 0.610 |
Why?
| | Analgesia | 1 | 2021 | 106 | 0.610 |
Why?
| | Thromboembolism | 1 | 2021 | 129 | 0.610 |
Why?
| | Adult | 31 | 2026 | 41087 | 0.600 |
Why?
| | Vitamins | 2 | 2019 | 183 | 0.600 |
Why?
| | Cholesterol, HDL | 1 | 2020 | 201 | 0.600 |
Why?
| | Hyperlactatemia | 1 | 2019 | 3 | 0.600 |
Why?
| | Bupropion | 1 | 2020 | 47 | 0.600 |
Why?
| | Pain Measurement | 2 | 2021 | 573 | 0.600 |
Why?
| | After-Hours Care | 1 | 2019 | 16 | 0.600 |
Why?
| | Anti-Infective Agents | 2 | 2022 | 234 | 0.600 |
Why?
| | Autism Spectrum Disorder | 2 | 2022 | 406 | 0.590 |
Why?
| | Antifibrinolytic Agents | 1 | 2020 | 68 | 0.590 |
Why?
| | Brain Ischemia | 2 | 2020 | 362 | 0.590 |
Why?
| | Hydrocortisone | 1 | 2021 | 303 | 0.590 |
Why?
| | Venous Thrombosis | 1 | 2021 | 199 | 0.590 |
Why?
| | Nonprescription Drugs | 1 | 2020 | 68 | 0.590 |
Why?
| | Vasopressins | 1 | 2019 | 60 | 0.590 |
Why?
| | Time Factors | 8 | 2025 | 7109 | 0.590 |
Why?
| | Carotid Stenosis | 1 | 2020 | 103 | 0.580 |
Why?
| | Bacteremia | 1 | 2021 | 218 | 0.580 |
Why?
| | Alzheimer Disease | 2 | 2026 | 641 | 0.580 |
Why?
| | Acidosis, Lactic | 1 | 2019 | 46 | 0.580 |
Why?
| | Coinfection | 1 | 2020 | 143 | 0.580 |
Why?
| | Analgesics, Opioid | 4 | 2026 | 1221 | 0.570 |
Why?
| | Acetylcysteine | 1 | 2019 | 139 | 0.570 |
Why?
| | Liver Failure, Acute | 1 | 2019 | 78 | 0.560 |
Why?
| | Complement C1 Inhibitor Protein | 1 | 2018 | 12 | 0.560 |
Why?
| | Dyslipidemias | 1 | 2020 | 184 | 0.560 |
Why?
| | Bradykinin | 1 | 2018 | 49 | 0.560 |
Why?
| | Urinary Tract Infections | 4 | 2025 | 209 | 0.550 |
Why?
| | Hypotension | 1 | 2019 | 125 | 0.550 |
Why?
| | Angioedema | 1 | 2018 | 16 | 0.550 |
Why?
| | Lidocaine | 1 | 2018 | 55 | 0.550 |
Why?
| | Patient Care Bundles | 1 | 2018 | 30 | 0.550 |
Why?
| | Fluid Therapy | 5 | 2019 | 154 | 0.550 |
Why?
| | Psychoses, Substance-Induced | 1 | 2018 | 16 | 0.550 |
Why?
| | Levofloxacin | 1 | 2018 | 21 | 0.550 |
Why?
| | Drug Overdose | 3 | 2019 | 377 | 0.540 |
Why?
| | Triglycerides | 1 | 2020 | 527 | 0.540 |
Why?
| | Veterans | 3 | 2025 | 1650 | 0.540 |
Why?
| | Cross Infection | 1 | 2020 | 258 | 0.530 |
Why?
| | Prescription Drugs | 1 | 2019 | 110 | 0.530 |
Why?
| | Administration, Oral | 3 | 2026 | 872 | 0.530 |
Why?
| | Anemia, Sickle Cell | 1 | 2021 | 324 | 0.510 |
Why?
| | Aged, 80 and over | 10 | 2025 | 8391 | 0.510 |
Why?
| | Venous Thromboembolism | 1 | 2021 | 332 | 0.510 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2018 | 228 | 0.510 |
Why?
| | Cohort Studies | 8 | 2025 | 6077 | 0.500 |
Why?
| | Calcium | 2 | 2023 | 1181 | 0.490 |
Why?
| | Cause of Death | 1 | 2019 | 456 | 0.490 |
Why?
| | Multiple Organ Failure | 1 | 2017 | 122 | 0.490 |
Why?
| | Metabolic Syndrome | 1 | 2020 | 364 | 0.490 |
Why?
| | Neuromuscular Blockade | 3 | 2026 | 53 | 0.470 |
Why?
| | Patient Care Team | 3 | 2026 | 701 | 0.470 |
Why?
| | Bone and Bones | 1 | 2019 | 319 | 0.460 |
Why?
| | Randomized Controlled Trials as Topic | 6 | 2021 | 1763 | 0.460 |
Why?
| | Vitamin K Deficiency Bleeding | 1 | 2015 | 5 | 0.460 |
Why?
| | Smoking Cessation | 1 | 2020 | 442 | 0.460 |
Why?
| | Dexmedetomidine | 3 | 2022 | 47 | 0.460 |
Why?
| | Thrombolytic Therapy | 3 | 2025 | 165 | 0.460 |
Why?
| | Intubation | 1 | 2015 | 7 | 0.450 |
Why?
| | Abdominal Abscess | 1 | 2015 | 28 | 0.440 |
Why?
| | Blood Coagulation | 2 | 2025 | 267 | 0.440 |
Why?
| | Statistics, Nonparametric | 3 | 2021 | 426 | 0.440 |
Why?
| | Designer Drugs | 1 | 2014 | 7 | 0.430 |
Why?
| | Intubation, Intratracheal | 3 | 2023 | 330 | 0.410 |
Why?
| | Heart-Assist Devices | 1 | 2020 | 572 | 0.410 |
Why?
| | BK Virus | 1 | 2014 | 18 | 0.410 |
Why?
| | Kidney Transplantation | 2 | 2026 | 735 | 0.410 |
Why?
| | Polyomavirus Infections | 1 | 2014 | 29 | 0.400 |
Why?
| | Tumor Virus Infections | 1 | 2014 | 51 | 0.400 |
Why?
| | Opportunistic Infections | 1 | 2014 | 47 | 0.400 |
Why?
| | Lactic Acid | 3 | 2023 | 295 | 0.400 |
Why?
| | Antiviral Agents | 1 | 2020 | 779 | 0.400 |
Why?
| | Dietary Supplements | 2 | 2019 | 587 | 0.400 |
Why?
| | Influenza, Human | 1 | 2020 | 640 | 0.390 |
Why?
| | Epinephrine | 2 | 2024 | 160 | 0.390 |
Why?
| | Hypertension | 2 | 2021 | 1272 | 0.380 |
Why?
| | Treatment Outcome | 9 | 2022 | 11821 | 0.380 |
Why?
| | Risk Factors | 8 | 2026 | 10921 | 0.380 |
Why?
| | Propensity Score | 2 | 2025 | 376 | 0.380 |
Why?
| | International Normalized Ratio | 3 | 2022 | 55 | 0.370 |
Why?
| | Peptides | 1 | 2018 | 992 | 0.370 |
Why?
| | Recombinant Proteins | 2 | 2025 | 1361 | 0.350 |
Why?
| | Pharmacy | 2 | 2023 | 32 | 0.350 |
Why?
| | Cytomegalovirus Infections | 1 | 2014 | 206 | 0.350 |
Why?
| | Length of Stay | 6 | 2025 | 1358 | 0.340 |
Why?
| | Respiratory Insufficiency | 1 | 2015 | 330 | 0.340 |
Why?
| | Incidence | 4 | 2021 | 2936 | 0.340 |
Why?
| | Emergency Medical Services | 1 | 2018 | 680 | 0.340 |
Why?
| | Blood Culture | 2 | 2023 | 27 | 0.320 |
Why?
| | Multivariate Analysis | 4 | 2019 | 1543 | 0.320 |
Why?
| | Intellectual Disability | 3 | 2021 | 183 | 0.320 |
Why?
| | Patient Discharge | 5 | 2024 | 997 | 0.310 |
Why?
| | Severity of Illness Index | 4 | 2020 | 2921 | 0.310 |
Why?
| | Peer Review | 2 | 2023 | 47 | 0.300 |
Why?
| | Wounds and Injuries | 2 | 2019 | 959 | 0.300 |
Why?
| | Logistic Models | 4 | 2019 | 2126 | 0.290 |
Why?
| | Patient Safety | 2 | 2026 | 352 | 0.280 |
Why?
| | Mentors | 3 | 2026 | 217 | 0.270 |
Why?
| | Prospective Studies | 5 | 2026 | 8123 | 0.260 |
Why?
| | Hospitals | 2 | 2026 | 738 | 0.260 |
Why?
| | Advanced Cardiac Life Support | 2 | 2024 | 28 | 0.240 |
Why?
| | Skin Diseases, Bacterial | 1 | 2026 | 22 | 0.240 |
Why?
| | Neurodevelopmental Disorders | 2 | 2021 | 239 | 0.240 |
Why?
| | Substance-Related Disorders | 2 | 2019 | 1100 | 0.240 |
Why?
| | Soft Tissue Infections | 1 | 2026 | 42 | 0.230 |
Why?
| | Medication Reconciliation | 1 | 2026 | 31 | 0.230 |
Why?
| | Digestive System Diseases | 1 | 2026 | 28 | 0.230 |
Why?
| | Personality Inventory | 1 | 2026 | 132 | 0.230 |
Why?
| | Chi-Square Distribution | 2 | 2019 | 517 | 0.230 |
Why?
| | Observational Studies as Topic | 2 | 2024 | 133 | 0.230 |
Why?
| | Postoperative Hemorrhage | 1 | 2026 | 106 | 0.220 |
Why?
| | Enterococcus | 1 | 2025 | 22 | 0.220 |
Why?
| | Inappropriate Prescribing | 1 | 2026 | 68 | 0.220 |
Why?
| | Hepatitis B Vaccines | 1 | 2025 | 43 | 0.220 |
Why?
| | Young Adult | 7 | 2026 | 14330 | 0.220 |
Why?
| | Paralysis | 1 | 2025 | 69 | 0.210 |
Why?
| | Immunoglobulins | 1 | 2025 | 162 | 0.210 |
Why?
| | Structure-Activity Relationship | 1 | 2026 | 563 | 0.210 |
Why?
| | Hepatitis B | 1 | 2025 | 66 | 0.210 |
Why?
| | Molecular Structure | 1 | 2026 | 484 | 0.210 |
Why?
| | Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2024 | 43 | 0.210 |
Why?
| | Cephalosporins | 1 | 2024 | 45 | 0.210 |
Why?
| | Gram-Positive Bacterial Infections | 1 | 2025 | 72 | 0.210 |
Why?
| | Ultrasonography, Interventional | 1 | 2026 | 163 | 0.210 |
Why?
| | Awareness | 1 | 2025 | 113 | 0.210 |
Why?
| | Administration, Intravenous | 1 | 2025 | 172 | 0.210 |
Why?
| | Spinal Cord Diseases | 1 | 2024 | 42 | 0.210 |
Why?
| | Vecuronium Bromide | 1 | 2024 | 8 | 0.210 |
Why?
| | Risk Assessment | 3 | 2020 | 3712 | 0.200 |
Why?
| | Academic Medical Centers | 2 | 2019 | 561 | 0.200 |
Why?
| | Survival Analysis | 2 | 2019 | 1378 | 0.200 |
Why?
| | Evidence-Based Medicine | 2 | 2026 | 731 | 0.200 |
Why?
| | Practice Guidelines as Topic | 4 | 2025 | 1591 | 0.200 |
Why?
| | Job Satisfaction | 1 | 2026 | 236 | 0.200 |
Why?
| | Patient Admission | 1 | 2025 | 216 | 0.200 |
Why?
| | Acute Disease | 1 | 2026 | 1038 | 0.190 |
Why?
| | Clinical Decision-Making | 1 | 2026 | 365 | 0.190 |
Why?
| | Pharmacy Residencies | 2 | 2019 | 10 | 0.190 |
Why?
| | Mass Casualty Incidents | 1 | 2023 | 52 | 0.190 |
Why?
| | Organizations | 1 | 2022 | 28 | 0.180 |
Why?
| | Epistaxis | 1 | 2022 | 16 | 0.180 |
Why?
| | Cystitis | 1 | 2022 | 24 | 0.180 |
Why?
| | Sex Offenses | 1 | 2025 | 199 | 0.180 |
Why?
| | Vitamin K | 1 | 2022 | 46 | 0.180 |
Why?
| | Exoribonucleases | 1 | 2023 | 48 | 0.180 |
Why?
| | Benzaldehydes | 1 | 2021 | 11 | 0.180 |
Why?
| | Hemoglobin, Sickle | 1 | 2021 | 20 | 0.180 |
Why?
| | Blood Coagulation Tests | 1 | 2022 | 72 | 0.170 |
Why?
| | Troponin | 1 | 2021 | 50 | 0.170 |
Why?
| | Microtubule-Associated Proteins | 1 | 2023 | 187 | 0.170 |
Why?
| | Disaster Planning | 1 | 2023 | 111 | 0.170 |
Why?
| | Myelitis, Transverse | 1 | 2021 | 4 | 0.170 |
Why?
| | Hearing Loss, Bilateral | 1 | 2021 | 12 | 0.170 |
Why?
| | Hearing Loss, Sudden | 1 | 2021 | 9 | 0.170 |
Why?
| | Propofol | 1 | 2022 | 86 | 0.170 |
Why?
| | Sexual Harassment | 1 | 2021 | 30 | 0.170 |
Why?
| | Megalencephaly | 1 | 2021 | 20 | 0.170 |
Why?
| | Pharmacies | 1 | 2021 | 40 | 0.170 |
Why?
| | Angiotensin II | 1 | 2021 | 102 | 0.170 |
Why?
| | Cardiopulmonary Resuscitation | 1 | 2024 | 334 | 0.160 |
Why?
| | Pharmaceutical Services | 1 | 2021 | 76 | 0.160 |
Why?
| | Pyrazines | 1 | 2021 | 94 | 0.160 |
Why?
| | Cerebral Hemorrhage, Traumatic | 1 | 2020 | 1 | 0.160 |
Why?
| | Hematoma, Subdural, Intracranial | 1 | 2020 | 2 | 0.160 |
Why?
| | Arthrogryposis | 1 | 2020 | 17 | 0.160 |
Why?
| | Bibliometrics | 1 | 2021 | 68 | 0.160 |
Why?
| | Subarachnoid Hemorrhage, Traumatic | 1 | 2020 | 5 | 0.160 |
Why?
| | Prader-Willi Syndrome | 1 | 2020 | 32 | 0.160 |
Why?
| | Antipsychotic Agents | 1 | 2022 | 185 | 0.160 |
Why?
| | Anesthesia, Local | 1 | 2020 | 27 | 0.160 |
Why?
| | Substance Withdrawal Syndrome | 1 | 2022 | 185 | 0.160 |
Why?
| | Electrocardiography | 1 | 2023 | 667 | 0.160 |
Why?
| | Mentoring | 1 | 2023 | 166 | 0.160 |
Why?
| | Creatinine | 1 | 2021 | 511 | 0.150 |
Why?
| | Biopsy, Needle | 1 | 2020 | 183 | 0.150 |
Why?
| | Mass Screening | 2 | 2018 | 1307 | 0.150 |
Why?
| | United States Department of Veterans Affairs | 1 | 2024 | 777 | 0.150 |
Why?
| | Craniocerebral Trauma | 1 | 2022 | 173 | 0.150 |
Why?
| | Rehydration Solutions | 1 | 2019 | 9 | 0.150 |
Why?
| | Ambulances | 1 | 2019 | 52 | 0.150 |
Why?
| | Drug Approval | 1 | 2020 | 94 | 0.150 |
Why?
| | Thyroid Nodule | 1 | 2020 | 67 | 0.150 |
Why?
| | Quality-Adjusted Life Years | 1 | 2019 | 122 | 0.150 |
Why?
| | Burnout, Professional | 1 | 2026 | 493 | 0.150 |
Why?
| | Anticonvulsants | 1 | 2022 | 253 | 0.150 |
Why?
| | Prognosis | 2 | 2020 | 4351 | 0.150 |
Why?
| | Respiration, Artificial | 2 | 2021 | 711 | 0.140 |
Why?
| | Vitamin D-Binding Protein | 1 | 2019 | 16 | 0.140 |
Why?
| | Surveys and Questionnaires | 4 | 2026 | 6073 | 0.140 |
Why?
| | Atrial Fibrillation | 2 | 2022 | 560 | 0.140 |
Why?
| | United States Food and Drug Administration | 1 | 2020 | 208 | 0.140 |
Why?
| | Patient Readmission | 1 | 2025 | 778 | 0.140 |
Why?
| | Prescription Drug Misuse | 1 | 2019 | 58 | 0.140 |
Why?
| | APACHE | 2 | 2016 | 67 | 0.140 |
Why?
| | Arterial Pressure | 1 | 2019 | 130 | 0.140 |
Why?
| | Kallikreins | 1 | 2018 | 25 | 0.140 |
Why?
| | Histamine Antagonists | 1 | 2018 | 21 | 0.140 |
Why?
| | Drug Therapy, Combination | 1 | 2021 | 1036 | 0.140 |
Why?
| | Sodium Chloride | 1 | 2019 | 138 | 0.140 |
Why?
| | Cost Savings | 1 | 2019 | 87 | 0.140 |
Why?
| | Students, Pharmacy | 1 | 2019 | 96 | 0.140 |
Why?
| | Hemodynamics | 1 | 2023 | 1114 | 0.140 |
Why?
| | Pelvic Bones | 1 | 2020 | 137 | 0.140 |
Why?
| | ROC Curve | 1 | 2020 | 617 | 0.140 |
Why?
| | Alcoholism | 2 | 2022 | 830 | 0.140 |
Why?
| | Pain Management | 1 | 2022 | 421 | 0.130 |
Why?
| | Renin-Angiotensin System | 1 | 2018 | 80 | 0.130 |
Why?
| | Rivaroxaban | 1 | 2020 | 270 | 0.130 |
Why?
| | Medicare | 2 | 2021 | 920 | 0.130 |
Why?
| | Patient Acceptance of Health Care | 1 | 2025 | 881 | 0.130 |
Why?
| | Registries | 2 | 2024 | 2400 | 0.130 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2026 | 1408 | 0.130 |
Why?
| | Reference Values | 1 | 2019 | 796 | 0.130 |
Why?
| | California | 1 | 2019 | 475 | 0.130 |
Why?
| | Disease Management | 1 | 2021 | 651 | 0.130 |
Why?
| | Educational Status | 1 | 2019 | 466 | 0.130 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2019 | 2022 | 0.130 |
Why?
| | Aspirin | 1 | 2020 | 405 | 0.120 |
Why?
| | Administration, Intranasal | 1 | 2017 | 95 | 0.120 |
Why?
| | Midazolam | 1 | 2017 | 69 | 0.120 |
Why?
| | Plasma | 1 | 2018 | 222 | 0.120 |
Why?
| | Algorithms | 1 | 2024 | 1849 | 0.120 |
Why?
| | Resuscitation | 1 | 2019 | 314 | 0.120 |
Why?
| | Cost-Benefit Analysis | 1 | 2019 | 640 | 0.120 |
Why?
| | Vaccination | 1 | 2025 | 1449 | 0.120 |
Why?
| | International Classification of Diseases | 1 | 2017 | 142 | 0.120 |
Why?
| | Patient Transfer | 1 | 2019 | 224 | 0.120 |
Why?
| | Socioeconomic Factors | 1 | 2021 | 1327 | 0.120 |
Why?
| | Gastrointestinal Diseases | 1 | 2018 | 220 | 0.120 |
Why?
| | Organizational Policy | 1 | 2016 | 76 | 0.120 |
Why?
| | Health Care Costs | 1 | 2019 | 423 | 0.120 |
Why?
| | Biomarkers | 2 | 2020 | 4340 | 0.120 |
Why?
| | Proteins | 2 | 2020 | 1022 | 0.120 |
Why?
| | Community-Acquired Infections | 1 | 2018 | 179 | 0.120 |
Why?
| | Waiting Lists | 1 | 2018 | 251 | 0.120 |
Why?
| | Double-Blind Method | 1 | 2021 | 2070 | 0.110 |
Why?
| | Fentanyl | 1 | 2017 | 126 | 0.110 |
Why?
| | Naloxone | 1 | 2017 | 139 | 0.110 |
Why?
| | Chicago | 1 | 2015 | 62 | 0.110 |
Why?
| | Injections, Intravenous | 1 | 2015 | 197 | 0.110 |
Why?
| | Publications | 1 | 2015 | 48 | 0.110 |
Why?
| | Motivation | 1 | 2019 | 605 | 0.110 |
Why?
| | Fractures, Bone | 1 | 2020 | 436 | 0.110 |
Why?
| | Ergocalciferols | 1 | 2014 | 15 | 0.110 |
Why?
| | Practice Patterns, Physicians' | 1 | 2024 | 1408 | 0.110 |
Why?
| | Magnetic Resonance Imaging | 2 | 2025 | 3926 | 0.110 |
Why?
| | Sex Distribution | 1 | 2015 | 382 | 0.100 |
Why?
| | Tomography, X-Ray Computed | 1 | 2025 | 2786 | 0.100 |
Why?
| | Cholecalciferol | 1 | 2014 | 60 | 0.100 |
Why?
| | Chromium | 1 | 2013 | 18 | 0.100 |
Why?
| | Manganese | 1 | 2013 | 59 | 0.100 |
Why?
| | Selenium | 1 | 2013 | 48 | 0.100 |
Why?
| | Michigan | 1 | 2014 | 203 | 0.100 |
Why?
| | Nutritional Requirements | 1 | 2013 | 78 | 0.100 |
Why?
| | Brain Concussion | 1 | 2022 | 660 | 0.100 |
Why?
| | Adolescent | 5 | 2026 | 22557 | 0.100 |
Why?
| | Copper | 1 | 2013 | 122 | 0.090 |
Why?
| | Research Design | 1 | 2019 | 1143 | 0.090 |
Why?
| | Parenteral Nutrition | 1 | 2013 | 102 | 0.090 |
Why?
| | Analysis of Variance | 1 | 2015 | 1298 | 0.090 |
Why?
| | Child | 6 | 2026 | 22693 | 0.090 |
Why?
| | Pneumonia | 1 | 2018 | 635 | 0.090 |
Why?
| | Electronic Health Records | 2 | 2019 | 1210 | 0.080 |
Why?
| | Iron | 1 | 2013 | 359 | 0.080 |
Why?
| | Wound Healing | 1 | 2013 | 354 | 0.080 |
Why?
| | Zinc | 1 | 2013 | 310 | 0.080 |
Why?
| | Societies, Medical | 2 | 2026 | 907 | 0.080 |
Why?
| | Mental Disorders | 1 | 2019 | 1148 | 0.080 |
Why?
| | Primary Health Care | 1 | 2021 | 1776 | 0.080 |
Why?
| | Antioxidants | 1 | 2013 | 544 | 0.080 |
Why?
| | Infant, Newborn | 2 | 2026 | 6460 | 0.080 |
Why?
| | Quality Improvement | 1 | 2018 | 1354 | 0.070 |
Why?
| | Immunosuppressive Agents | 1 | 2014 | 829 | 0.070 |
Why?
| | Brain Injuries, Traumatic | 2 | 2026 | 466 | 0.070 |
Why?
| | Intrinsically Disordered Proteins | 2 | 2020 | 49 | 0.070 |
Why?
| | Syndrome | 2 | 2021 | 380 | 0.070 |
Why?
| | Pregnancy | 1 | 2022 | 7230 | 0.070 |
Why?
| | Sex Factors | 1 | 2014 | 2107 | 0.070 |
Why?
| | Age Factors | 1 | 2014 | 3347 | 0.060 |
Why?
| | Cross-Sectional Studies | 3 | 2026 | 5899 | 0.060 |
Why?
| | Fasciitis, Necrotizing | 1 | 2026 | 16 | 0.060 |
Why?
| | Intracellular Signaling Peptides and Proteins | 2 | 2020 | 457 | 0.060 |
Why?
| | Cellulitis | 1 | 2026 | 55 | 0.060 |
Why?
| | Potentially Inappropriate Medication List | 1 | 2026 | 17 | 0.060 |
Why?
| | Animals | 2 | 2022 | 38107 | 0.060 |
Why?
| | Abscess | 1 | 2026 | 77 | 0.060 |
Why?
| | Carboxylic Ester Hydrolases | 1 | 2025 | 24 | 0.060 |
Why?
| | Drainage | 1 | 2026 | 187 | 0.060 |
Why?
| | Urinalysis | 1 | 2025 | 82 | 0.050 |
Why?
| | Neurology | 1 | 2026 | 107 | 0.050 |
Why?
| | Intensive Care Units, Pediatric | 1 | 2026 | 293 | 0.050 |
Why?
| | Preoperative Care | 1 | 2026 | 396 | 0.050 |
Why?
| | Shock, Cardiogenic | 1 | 2023 | 65 | 0.050 |
Why?
| | Citric Acid | 1 | 2023 | 33 | 0.050 |
Why?
| | Peer Review, Research | 1 | 2023 | 36 | 0.050 |
Why?
| | Hypocalcemia | 1 | 2023 | 40 | 0.050 |
Why?
| | Shock | 1 | 2023 | 101 | 0.050 |
Why?
| | Diphenhydramine | 1 | 2022 | 36 | 0.050 |
Why?
| | Fluoroquinolones | 1 | 2022 | 44 | 0.050 |
Why?
| | beta-Lactamases | 1 | 2022 | 54 | 0.040 |
Why?
| | Inpatients | 1 | 2026 | 540 | 0.040 |
Why?
| | Patient Satisfaction | 1 | 2026 | 706 | 0.040 |
Why?
| | Chronic Pain | 1 | 2026 | 304 | 0.040 |
Why?
| | Phenotype | 2 | 2020 | 3206 | 0.040 |
Why?
| | Drug Resistance, Bacterial | 1 | 2022 | 185 | 0.040 |
Why?
| | Microbial Sensitivity Tests | 1 | 2022 | 367 | 0.040 |
Why?
| | Peer Group | 1 | 2023 | 251 | 0.040 |
Why?
| | Guideline Adherence | 1 | 2025 | 594 | 0.040 |
Why?
| | Gender Identity | 1 | 2021 | 132 | 0.040 |
Why?
| | Education, Pharmacy, Graduate | 1 | 2019 | 13 | 0.040 |
Why?
| | Emotional Intelligence | 1 | 2019 | 13 | 0.040 |
Why?
| | Blood Transfusion | 1 | 2023 | 394 | 0.040 |
Why?
| | Hospitals, Psychiatric | 1 | 2019 | 25 | 0.040 |
Why?
| | Chronic Disease | 1 | 2026 | 1827 | 0.040 |
Why?
| | Back Pain | 1 | 2019 | 58 | 0.040 |
Why?
| | Chest Pain | 1 | 2019 | 100 | 0.040 |
Why?
| | Medically Uninsured | 1 | 2019 | 134 | 0.040 |
Why?
| | Frameshift Mutation | 1 | 2018 | 32 | 0.040 |
Why?
| | Infant | 2 | 2026 | 10114 | 0.030 |
Why?
| | Alcoholic Intoxication | 1 | 2019 | 78 | 0.030 |
Why?
| | Renal Replacement Therapy | 1 | 2019 | 102 | 0.030 |
Why?
| | Abdominal Pain | 1 | 2019 | 149 | 0.030 |
Why?
| | Codon, Nonsense | 1 | 2018 | 46 | 0.030 |
Why?
| | Bias | 1 | 2019 | 197 | 0.030 |
Why?
| | Escherichia coli | 1 | 2022 | 832 | 0.030 |
Why?
| | Child, Preschool | 2 | 2026 | 11913 | 0.030 |
Why?
| | Physicians | 1 | 2026 | 955 | 0.030 |
Why?
| | Disability Evaluation | 1 | 2019 | 297 | 0.030 |
Why?
| | Education, Pharmacy | 1 | 2019 | 125 | 0.030 |
Why?
| | Health Services Needs and Demand | 1 | 2019 | 287 | 0.030 |
Why?
| | Laboratories, Hospital | 1 | 2016 | 14 | 0.030 |
Why?
| | Genetic Association Studies | 1 | 2018 | 379 | 0.030 |
Why?
| | Health Personnel | 1 | 2023 | 754 | 0.030 |
Why?
| | Nervous System Diseases | 1 | 2019 | 288 | 0.030 |
Why?
| | Early Medical Intervention | 1 | 2016 | 59 | 0.030 |
Why?
| | Telephone | 1 | 2016 | 175 | 0.030 |
Why?
| | Early Diagnosis | 1 | 2016 | 251 | 0.030 |
Why?
| | Medicaid | 1 | 2019 | 477 | 0.030 |
Why?
| | Prevalence | 1 | 2022 | 2861 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2019 | 1503 | 0.030 |
Why?
| | Recovery of Function | 1 | 2019 | 725 | 0.030 |
Why?
| | Internet | 1 | 2019 | 660 | 0.030 |
Why?
| | Health Status | 1 | 2019 | 827 | 0.020 |
Why?
| | Mortality | 1 | 2016 | 375 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2019 | 2113 | 0.020 |
Why?
| | Hospitals, Teaching | 1 | 2014 | 121 | 0.020 |
Why?
| | Tertiary Care Centers | 1 | 2014 | 196 | 0.020 |
Why?
| | Parents | 1 | 2021 | 1394 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2019 | 3647 | 0.020 |
Why?
| | Acute Kidney Injury | 1 | 2019 | 866 | 0.020 |
Why?
| | Kidney Failure, Chronic | 1 | 2014 | 589 | 0.020 |
Why?
|
|
Rech's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|